NASDAQ:STOK

Stoke Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy STOK

*Your capital is at risk

$28.86

-1.18 (-3.93%)

At Close: Jul 31, 2026

Stoke Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 7.48. In total, the insiders bought 1.57M and sold 268.45K STOK shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	7.48
● Buy	1.57M shares
● Sell	268.45K shares
55% Buy Activity Strong Positive Correlation
Buy Signal Medium Confidence Jul 15, 2026 Analysis Breakdown: Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 16, 2026 Buy	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	7 639 Value: $125.4K
Jul 16, 2026 Sell	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	19 441 Value: $242.2K
Jul 16, 2026 Sell	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	14 777 Value: $392.0K
Jul 16, 2026 Sell	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	11 650 Value: $470.3K
Jul 16, 2026 Sell	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	21 000 Value: $272.2K
Jul 16, 2026 Sell	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	29 555 Value: $851.2K
Jul 16, 2026 Sell	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	7 639 Value: $125.4K
Jul 16, 2026 Sell	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	29 747 Value: $324.2K
Jul 16, 2026 Sell	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	17 786 Value: $524.0K
Jul 16, 2026 Buy	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	11 650 Value: $470.3K
Jul 16, 2026 Buy	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	14 777 Value: $392.0K
Jul 16, 2026 Buy	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	17 786 Value: $524.0K
Jul 16, 2026 Buy	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	19 441 Value: $242.2K
Jul 16, 2026 Buy	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	21 000 Value: $272.2K
Jul 16, 2026 Buy	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	29 555 Value: $851.2K
Jul 16, 2026 Buy	Stock Option (Right to Buy) G-Gift	Harrison Seth Loring Director	Director	29 747 Value: $324.2K
Jul 15, 2026 Buy	Stock Option (Right to Buy) A-Award	Mccauley Thomas Chief Scientific Officer	Officer	225 000 Value: $6.73M
Jul 13, 2026 Buy	Common Stock J-Other	Mccauley Thomas Insider	Other	0 Value: $0
Jul 01, 2026 Sell	Common Stock S-Sale	Ticho Barry Chief Medical Officer	Officer	500 Value: $16.6K
Jul 01, 2026 Sell	Common Stock S-Sale	Ticho Barry Chief Medical Officer	Officer	6 728 Value: $219.4K
Jun 16, 2026 Sell	Common Stock S-Sale	Allan Jonathan General Counsel & Corp Sec	Officer	1 457 Value: $43.6K
Jun 03, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Kaye Edward M. Md Director	Director	17 786 Value: $524.0K
Jun 03, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Harrison Seth Loring Director	Director	17 786 Value: $524.0K
Jun 03, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Burstein Jennifer Director	Director	17 786 Value: $524.0K
Jun 03, 2026 Buy	Director Stock Option (Right to Buy) A-Award	Levin Arthur A Director	Director	17 786 Value: $524.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT STOKE THERAPEUTICS, INC.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,...

Read Full Profile Here